Valuation: Amgen Inc.

Market Cap 224B 201B 187B 170B 320B 21,441B 322B 2,249B 881B 11,064B 843B 824B 35,605B P/E 2026 *
26.3x
P/E 2027 * 23.5x
Enterprise Value 266B 238B 222B 201B 380B 25,413B 382B 2,666B 1,044B 13,114B 999B 976B 42,200B EV / Sales 2026 *
6.83x
EV / Sales 2027 * 6.45x
Free-Float
99.77%
Yield 2026 *
2.43%
Yield 2027 * 2.57%
1 day+2.20%
1 week+3.02%
Current month-1.44%
1 month+9.92%
3 months+13.91%
6 months+17.35%
Current year+23.59%
1 week 29.58
Extreme 29.58
30.74
1 month 27.73
Extreme 27.73
31.38
Current year 23.95
Extreme 23.95
32.94
1 year 23.95
Extreme 23.95
32.94
3 years 23.95
Extreme 23.95
32.94
5 years 23.95
Extreme 23.95
32.94
10 years 23.95
Extreme 23.95
32.94
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+2.20%+3.02% - - 224B
+0.21%+3.05%+43.76%+92.96% 1,051B
+0.71%+4.03%+37.83%+68.31% 630B
+1.11%+5.26%+21.47%+88.64% 489B
-0.27%+4.01%+69.35%+40.11% 359B
+0.61%+3.18%+24.10%+42.46% 344B
+0.72%+2.99%+14.79%+34.71% 272B
+0.23%+2.23%-5.49%+8.15% 246B
+0.13%+3.14%+42.15%+45.82% 224B
-0.62%+3.95%+27.19%+95.87% 187B
Average +0.44%+2.86%+30.57%+57.45% 422.63B
Weighted average by Cap. +0.45%+2.93%+34.38%+66.46%

Financials

2026 *2027 *
Net sales 38.95B 34.87B 32.5B 29.48B 55.61B 3,723B 55.96B 391B 153B 1,921B 146B 143B 6,183B 40.36B 36.13B 33.68B 30.55B 57.62B 3,858B 57.98B 405B 158B 1,991B 152B 148B 6,407B
Net income 8.53B 7.64B 7.12B 6.46B 12.18B 815B 12.26B 85.56B 33.49B 421B 32.05B 31.34B 1,354B 9.39B 8.41B 7.84B 7.11B 13.41B 898B 13.49B 94.17B 36.86B 463B 35.27B 34.49B 1,491B
Net Debt 41.55B 37.2B 34.68B 31.45B 59.32B 3,972B 59.69B 417B 163B 2,050B 156B 153B 6,596B 35.9B 32.14B 29.96B 27.17B 51.25B 3,432B 51.57B 360B 141B 1,771B 135B 132B 5,698B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
09/10/26 CA$30.70 +2.20% 6,629
08/10/26 CA$30.04 -1.25% 1,771
07/10/26 CA$30.42 +2.39% 2,913
06/10/26 CA$29.71 -0.30% 903
05/10/26 CA$29.80 0.00% 437
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
414.87USD
Average target price
395.25USD
Spread / Average Target
-4.73%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.